SpringWorks Therapeutics’ SWTX oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company focusing on cancer and severe rare diseases. OGSIVEO (nirogacestat) is its FDA-approved therapy for ...

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang ...

SpringWorks launched last year with $103 million in financing, led by Bain Capital, OrbiMed Advisors and Pfizer Inc., and a plan to develop treatments for patients who lack good treatment options.

SpringWorks Therapeutics, Inc. (SWTX), the Stamford, Conn.,-based biotech that launched its initial public offering ("IPO") in September 2019, raising ~$186 via the issuance of 10.35m shares ...

SpringWorks has set a wholesale acquisition cost for GOMEKLI at $206.25 per mg. The company estimates that the average cost of treatment will be approximately $22,000 per month for pediatric ...

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of non ...